证券代码：300026 证券简称：红日药业 编号：2020-03 天津红日药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | ■ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 渤海证券 郑翔 姜财义 刘志明 张雄云 马振华 马强 | | 人员姓名 | 国融证券 崔峻 菲徐静 | | | | 中信证券 蔡丽萍 闫勇吕伟 | | | | 大通证券 刘加军 张荷俊 | | | | 长江证券 潘霍喜 | | | | 中银证券 许康 张文光 | | | | 国信证券 姜鹏 许允 孙静 王一晗 | | | | 兴业证券 黄勇 王云鹏 | | | | 国泰君安证券 韩玉玺 范纬华 | | | | ...

证券代码：300026 证券简称：红日药业 编号：2020-02 1 天津红日药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|--------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | ■ 其他 （电话会议） | | | 参与单位名称及 | 东兴证券 胡博新 王敏杰 | | | 人员姓名 | 华夏基金 张帆 | | | | 建信养老金 王新艳 | | | | 人寿养老 张树声 | | | | 天弘基金 郭相博 | | | | 诺安基金 陈勇 | | | | 人保资产 黄鑫 | | | | 东北证券 华锦东 | | | | 国信证券 余方升 | | | | 平安证券 李峰 | | | | 北京新华联产 甄荣军 | | | | 懋石资产 袁一飞 | | | | 渤海汇金 纪钢 | | | --- ...

Financial Performance - The company's revenue for Q3 2022 was ¥1,588,644,754.71, representing a decrease of 20.58% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥118,289,981.94, down 40.63% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,572,170.92, a decrease of 50.00% compared to the previous year[7] - Total operating revenue for the third quarter was CNY 4,900,224,293.30, a decrease of 10.67% compared to CNY 5,486,439,217.46 in the same period last year[30] - The net profit for the current period is 469,484,920.92, a decrease of 25.2% compared to 627,306,052.40 in the previous period[32] - The total profit for the current period is 571,274,481.71, down from 766,195,077.14, reflecting a decline of 25.5%[32] - The operating profit for the current period is 542,007,469.41, compared to 754,222,342.94 in the previous period, indicating a decrease of 28.1%[32] - The total comprehensive income for the current period is 489,833,240.84, compared to 629,052,999.17 in the previous period, a decrease of 22.2%[35] - Basic earnings per share for the current period is 0.16, down from 0.21, reflecting a decline of 23.8%[35] Research and Development - R&D expenses for the period amounted to ¥176,091,200, an increase of 52.06% year-on-year, indicating increased investment in research and development[14] - Research and development expenses increased to CNY 176,091,216.83, up from CNY 115,803,855.49, indicating a focus on innovation and new product development[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,995,272,284.07, reflecting a growth of 3.34% from the end of the previous year[7] - The total assets reached CNY 11,995,272,284.07, compared to CNY 11,607,300,738.29 in the previous year, showing growth in asset base[29] - Non-current assets totaled CNY 5,111,440,203.53, an increase from CNY 4,801,037,420.21, highlighting investment in long-term assets[29] - The company's total liabilities were CNY 3,676,580,575.85, slightly up from CNY 3,654,921,077.43, indicating stable financial leverage[29] - The equity attributable to shareholders increased to CNY 8,143,563,383.56 from CNY 7,772,888,664.89, reflecting improved profitability and retained earnings[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥252,779,423.82, down 33.83% compared to the same period last year[7] - The cash flow from operating activities for the current period is 252,779,423.82, down from 382,031,160.81, a decline of 33.9%[36] - The cash flow from investing activities shows a net outflow of -508,830,755.94, compared to -397,030,866.12 in the previous period, indicating an increase in outflow[38] - The cash flow from financing activities has a net outflow of -104,473,550.90, contrasting with a net inflow of 566,554,801.03 in the previous period[38] - The total cash and cash equivalents at the end of the period is 956,712,079.30, down from 1,635,365,692.54, a decrease of 41.5%[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 138,546, with a total shareholding of 243,820,162 shares pledged[16] - The company reported a total of 305,408,770 restricted shares, with 873,750 shares released during the period[22] - The top shareholder, Chengdu Xingcheng Investment Group Co., Ltd., holds 667,997,417 shares, representing a significant portion of the company's equity[22] - The total number of restricted shares held by the top 10 shareholders remains unchanged at 294,196,979 shares for Yao Xiaoqing[19] Strategic Developments - The company has no new strategies or significant events reported in the third quarter[25] - The company has not reported any new product developments or technological advancements in the latest quarter[25] - There are no mergers or acquisitions mentioned in the third quarter report[25] - The company is exploring market expansion opportunities, although specific strategies were not disclosed in the report[30] - The company maintained a strong cash position, with cash flow metrics to be elaborated in subsequent disclosures, ensuring liquidity for future investments[30] Other Financial Metrics - The weighted average return on equity was 1.46%, down 1.16% from the previous year[7] - The company reported a significant increase in prepayments, which rose by 54.92% year-on-year, indicating higher procurement payments[12] - As of September 30, 2022, the total current assets amounted to CNY 6,883,832,080.54, an increase from CNY 6,806,263,318.08 at the beginning of the year[23] - The cash and cash equivalents decreased to CNY 976,261,663.49 from CNY 1,315,964,613.66 at the beginning of the year[23] - Accounts receivable stood at CNY 3,292,614,423.39, down from CNY 3,506,551,341.00 at the start of the year[23] - Inventory increased to CNY 1,849,163,017.45 from CNY 1,304,511,820.13 at the beginning of the year[23] - The company reported a foreign currency translation difference of 16,990,172.50, compared to -2,510,018.74 in the previous period, indicating a positive change[35]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the first half of 2022, representing a year-on-year increase of 15%[19] - Net profit attributable to shareholders reached RMB 300 million, up 10% compared to the same period last year[19] - The company has set a revenue target of RMB 3 billion for the full year 2022, indicating a growth forecast of 12%[19] - The company achieved a revenue of 3.312 billion yuan in 2022, a decrease of 5.01% year-on-year[54] - The operating profit for the company was 385 million yuan, down 26.16% compared to the previous year[54] - The total profit amounted to 406 million yuan, reflecting a decline of 23.94% year-on-year[54] - The net profit attributable to shareholders was 352 million yuan, a decrease of 19.56% year-on-year[54] - The company's operating revenue for the reporting period was ¥3,311,579,538.59, a decrease of 5.01% compared to the same period last year[34] - Net profit attributable to shareholders was ¥352,202,610.29, down 19.56% year-on-year[34] - The net profit after deducting non-recurring gains and losses was ¥311,197,919.12, reflecting a decline of 26.72% compared to the previous year[34] Research and Development - The company plans to invest RMB 200 million in R&D for new products and technologies in the upcoming year[19] - Research and development investments increased by 25%, focusing on innovative traditional Chinese medicine products[25] - The company has over 30 ongoing research projects and has submitted more than 5 projects for review by the CDE[48] - The company's R&D investment increased by 26.98% to ¥142,696,420.19, primarily due to improved sales collection[77] - The company is actively pursuing research and development collaborations and overseas investments to introduce advanced wearable health products[67] Market Expansion - User data indicates a growth of 20% in active users of the company's health management services[19] - The company has expanded its market presence by opening 50 new retail locations across various provinces[19] - The company plans to expand its market presence by opening 50 new clinics across China by the end of 2023[25] - The company is exploring potential acquisitions in the healthcare sector to diversify its product portfolio[25] - The company is focusing on enhancing its digital health services to capture a larger market share in the telemedicine sector[19] Product Development - A strategic acquisition of a local pharmaceutical company was completed, enhancing the company's product portfolio[19] - New product launches are expected to contribute an additional CNY 200 million in revenue by Q4 2022[25] - The innovative drug "Xuebijing Injection" has shown a survival rate of 91.7% in severe COVID-19 patients and is included in the National Medical Insurance Drug List[46] - The company has launched a new product, Bopuning (Enoxaparin Sodium Injection), which started nationwide listing work in March[63] - The company has a diverse product portfolio with 28 varieties across 11 categories, including anti-tumor drugs and central nervous system medications, with significant market potential[64] Financial Management - The company will not distribute cash dividends or issue bonus shares for this fiscal year[6] - The net cash flow from operating activities increased by 53.22% to ¥302,646,059.70[34] - The company's cash flow from investment activities increased by 53.22% to ¥302,646,059.70, indicating enhanced investment activities[77] - The inventory increased by 31.84% to ¥1,719,822,700.43, mainly due to an increase in stock of goods and raw materials[82] - The company reported a 44.84% decrease in income tax expenses to ¥57,036,581.68, resulting from reduced tax liabilities during the period[77] Environmental Compliance - The company operates under strict environmental regulations, ensuring compliance with various pollutant discharge standards[144] - The company has updated its pollutant discharge permit as of December 3, 2021, ensuring compliance with environmental regulations[168] - The company has established a comprehensive safety production policy, achieving its safety production goals during the reporting period[172] - The company has developed and revised its environmental self-monitoring plan in accordance with pollutant discharge requirements, ensuring timely completion and public disclosure[169] Corporate Governance - The company fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[179] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[182] - The company did not have any major litigation or arbitration matters during the reporting period[186] - There were no significant related party transactions during the reporting period[188] - The company did not engage in any asset or equity acquisitions or sales during the reporting period[189]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2022-044 天津红日药业股份有限公司 关于参加"2022年度天津辖区上市公司半年报业绩说明会与 投资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津红日药业股份有限公司（以下简称 "公司"）定于2022年9月6日（星期二）15:00-16:30参加由天津证监局主办、天 津上市公司协会与深圳市全景网络有限公司协办的"2022年度天津辖区上市公司 半年报业绩说明会与投资者网上集体接待日"活动，现将有关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可以登录"全景路演" （http://rs.p5w.net）参与本次互动交流。 出席本次"2022年度天津辖区上市公司半年报业绩说明会与投资者网上集体 接待日"活动的人员有：公司副董事长、董事兼总经理郑丹女士，公司董事、副 总经理、财务负责人兼董事会秘书蓝武军先生。 欢迎广大投资者积极参与。 特此公告。 天津红日药业股份有限公司 董 事 会 二○二二年八月二十九日 ...

Financial Performance - The company's revenue for Q1 2022 was CNY 1,732,429,393.62, representing a 5.70% increase compared to CNY 1,638,989,465.00 in the same period last year[3] - Net profit attributable to shareholders was CNY 238,237,011.30, up 23.34% from CNY 193,160,182.56 year-on-year[3] - Basic earnings per share increased by 33.33% to CNY 0.08 from CNY 0.06 in the same quarter last year[3] - Net profit for the quarter reached CNY 239,797,479.73, compared to CNY 190,354,392.50 in the same period last year, reflecting a growth of approximately 26%[28] - The total comprehensive income attributable to the parent company was CNY 237,091,893.50, compared to CNY 193,747,016.67 in the previous period, representing an increase of approximately 22.4%[31] Cash Flow - The net cash flow from operating activities reached CNY 176,142,534.52, reflecting a 17.91% increase from CNY 149,389,822.89 in the previous year[3] - Cash inflow from operating activities totaled CNY 2,003,293,616.45, up from CNY 1,780,137,951.91, indicating an increase of about 12.5%[32] - The total cash outflow from operating activities was CNY 1,827,151,081.93, compared to CNY 1,630,748,129.02 in the previous period, indicating an increase of approximately 12.0%[35] - The net cash flow from investment activities was CNY -173,811,000.00, a decrease of 70.17% compared to the previous year, attributed to increased capital expenditures[6] - The net cash flow from financing activities was CNY -106,793,165.04, a decline from CNY 11,105,745.81 in the previous period[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,756,400,108.61, a 1.28% increase from CNY 11,607,300,738.29 at the end of the previous year[3] - The company's total liabilities decreased to CNY 3,565,368,085.82 from CNY 3,654,921,077.43, a reduction of about 2.4%[24] - The company's equity attributable to shareholders rose by 3.05% to CNY 8,009,980,558.39 from CNY 7,772,888,664.89 at the end of last year[3] - Total current assets reached ¥6,973,463,669.56, compared to ¥6,806,263,318.08 at the beginning of the year[18] - Non-current assets total ¥4,782,936,439.05, down from ¥4,801,037,420.21[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 201,710[10] - Chengdu Xingcheng Investment Group Co., Ltd. holds 22.24% of shares, totaling 667,997,417 shares[10] - The number of restricted shares held by major shareholders decreased, with Yao Xiaoqing holding 294,196,979 shares after a release of 14,664,750 shares[14] Expenses - Total operating costs amounted to CNY 1,494,467,728.84, up from CNY 1,413,767,708.74, indicating an increase of about 5.7%[24] - Research and development expenses for the quarter were CNY 51,569,849.88, up from CNY 41,084,903.84, indicating an increase of about 25.5%[24] - The company reported a tax expense of CNY 44,364,341.86, compared to CNY 39,271,528.49 in the previous period, which is an increase of approximately 13.5%[28] - Financial expenses increased by 38.65% to CNY 18,212,800.00, mainly due to higher interest expenses[6] Other Income and Gains - Non-recurring gains and losses totaled CNY 35,192,383.61 for the period, primarily due to government subsidies received[5] - The company reported a significant increase in other income, which rose by 233.82% to CNY 20,770,500.00, mainly from government subsidies[6] Market Strategy - The company has no new strategies or significant market expansions reported in the current quarter[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]

Financial Performance - The company reported a profit distribution plan to distribute a cash dividend of 0.40 CNY per 10 shares based on a total of 3,004,154,837 shares[12]. - Tianjin Hongri Pharmaceutical Co., Ltd. reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-on-year increase of 15%[23]. - The company achieved a net profit of RMB 300 million in 2021, which is a 20% increase compared to the previous year[23]. - The company has set a revenue target of RMB 1.5 billion for 2022, reflecting a growth forecast of 25%[23]. - The gross margin improved to 40% in 2021, up from 35% in the previous year, due to cost control measures and operational efficiencies[23]. - The company's operating revenue for 2021 was ¥7,670,525,029.35, representing an increase of 18.22% compared to ¥6,488,115,933.34 in 2020[5]. - The net profit attributable to shareholders for 2021 was ¥687,316,929.01, up 19.87% from ¥573,394,032.25 in 2020[5]. - The net cash flow from operating activities reached ¥391,598,803.37, showing a remarkable growth of 99.12% from ¥196,661,909.63 in 2020[5]. - The total assets at the end of 2021 were ¥11,607,300,738.29, reflecting a growth of 14.02% from ¥10,179,628,487.94 at the end of 2020[5]. - The company achieved a revenue of 7.671 billion yuan, representing a year-on-year growth of 18.22%[67]. Research and Development - The company is focusing on enhancing its research and development capabilities to adapt to the evolving pharmaceutical policies and market opportunities, particularly in traditional Chinese medicine[6]. - The company is investing RMB 100 million in R&D for new technologies aimed at enhancing product efficacy and safety[23]. - The company has over 30 ongoing research projects and more than 500 effective patents in the field of innovative drugs[61]. - The company has filed over 30 invention patents related to traditional Chinese medicine processing technology, showcasing its commitment to innovation[81]. - The company is actively involved in the development of national and provincial standards for traditional Chinese medicine granules, contributing to industry standardization[80]. Market Expansion - The medical device business is expanding both domestically and internationally, with a focus on adapting to varying medical and tariff policies in different regions[9]. - The company is exploring international markets, with plans to enter Southeast Asia by the end of 2022, targeting an initial revenue of RMB 50 million from this region[23]. - Market expansion efforts have led to the establishment of 50 new sales outlets across various provinces in China, increasing market penetration by 30%[23]. - The company is actively enhancing its product optimization and process improvement in response to the international pharmaceutical industry chain restructuring[64]. - The company has established a comprehensive sales network globally, with subsidiaries in the US, Germany, Canada, India, and Singapore, enhancing local market access[86]. Product Development - The company plans to launch three new products in 2022, focusing on traditional Chinese medicine, which is expected to contribute an additional RMB 200 million in revenue[23]. - The company has a diverse product portfolio with 28 varieties across 11 categories, including traditional Chinese medicine and various therapeutic drugs, indicating a significant market presence[80]. - The leading products, such as Xuebijing injection and Moxifloxacin sodium chloride injection, have clear clinical efficacy and quality control, enhancing competitive advantages in the market[80]. - The company has received multiple approvals for new drugs, including the approval of 4 new chemical drugs in 2021, expanding its product line and market reach[80]. Sustainability and Compliance - The company is committed to sustainable development and environmental protection, aligning with stricter regulations on pollution control[8]. - The company is actively participating in the formulation of national standards for traditional Chinese medicine to seize industry opportunities[8]. - The company has established a comprehensive quality control system for its traditional Chinese medicine granules, ensuring safety and efficacy through rigorous standards[85]. - The company has implemented modern production technologies, achieving automation in the production of Xuebijing injection, which enhances product quality and risk control[81]. Digital Transformation - The company is developing a market-oriented industrial internet service platform to improve operational efficiency across its business segments[11]. - The company is focusing on digital transformation initiatives to enhance customer engagement and streamline operations[32]. - The company is leveraging big data applications across its product lines to transform from a traditional manufacturer to a comprehensive health service provider[55]. - The company is committed to building an integrated online and offline traditional Chinese medicine service system, focusing on user-centered healthcare experiences[187]. Financial Management - The company has a performance evaluation and incentive mechanism in place for senior management, linking compensation directly to performance outcomes[200]. - The company has established a transparent information disclosure system, ensuring compliance with relevant laws and regulations[200]. - The company has maintained a healthy balance of raised funds, ensuring sufficient liquidity for ongoing and future projects[144]. - The company has signed tripartite supervision agreements to ensure the proper management of raised funds with relevant financial institutions[156].

天津红日药业股份有限公司 2021 年第三季度报告 证券代码：300026 证券简称：红日药业 公告编号：2021-065 天津红日药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|-------------------|-------------------------|--------------------------|----- ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[21]. - Net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[21]. - The company's operating revenue for the reporting period was CNY 3,486,236,923.44, representing a 25.31% increase compared to CNY 2,782,174,792.94 in the same period last year[36]. - The net profit attributable to shareholders of the listed company was CNY 437,852,638.83, up 27.37% from CNY 343,775,227.67 year-on-year[36]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 424,650,002.29, reflecting a significant increase of 46.43% compared to CNY 289,997,587.71 in the previous year[36]. - Basic earnings per share were CNY 0.15, representing a 36.36% increase from CNY 0.11 in the previous year[36]. - The company achieved a revenue of 3.486 billion yuan, representing a year-on-year growth of 25.31%[54]. - The net profit attributable to shareholders reached 438 million yuan, an increase of 27.37% compared to the previous year[54]. Research and Development - The company plans to invest RMB 200 million in R&D for new products and technologies in the upcoming year[21]. - The company's R&D investment amounted to ¥112,379,109.31, reflecting a 26.30% increase compared to the previous year[75]. - The company has several key drug development projects, including KB for sepsis treatment in phase IIb clinical research and PTS for anti-tumor currently under review[61]. - The company has 20+ ongoing research projects, including 5 Class 1 new drug projects, with 11 projects submitted to CDE awaiting review[74]. - The company has submitted research materials for 10 varieties of formula granules for national standard approval, with 13 varieties undergoing supplementary research[46]. - The company is actively involved in the development of new products and technologies in the medical device sector, with a rich pipeline of projects[49]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting an additional 10 provinces by the end of 2022[21]. - The management has set a revenue growth target of 10% for the second half of 2021[21]. - The company is focusing on enhancing its supply chain efficiency to reduce costs by 5%[21]. - The company has expanded its offline medical institutions to cover nearly 20 provinces and cities, with a total of 187 franchise medical institutions[50]. - The company is actively developing a comprehensive supply chain service platform, integrating financial technology, medical supplies, and logistics services[51]. - The company is focusing on expanding its smart supply chain business and increasing market coverage through self-operated products[58]. Product Development and Innovation - A new product line is expected to launch in Q4 2021, projected to contribute an additional RMB 100 million in revenue[21]. - The company has launched 19 new products in the medical device sector and obtained 6 domestic registration certificates[56]. - The company emphasizes the development of proprietary medical devices, focusing on advanced technologies such as ECG algorithms and new material sensors[118]. - The company has developed over 600 types of traditional Chinese medicine formula granules, covering the most frequently used varieties in clinical practice[46]. - The company’s main products include Xuebijing injection, which is approved for treating severe conditions like sepsis and COVID-19, and has received a first-class scientific progress award[46]. Financial Management and Investments - The total amount of investment during the reporting period was ¥3,700,000.00, a significant decrease of 95.02% compared to ¥74,230,000.00 in the same period last year[88]. - The total amount of raised funds was ¥181,926,000, with ¥822.41 million invested during the reporting period, and a cumulative investment of ¥153,431.01 million[90]. - The company has invested ¥75,521.02 million in the automation production base project for traditional Chinese medicine products[94]. - The total committed investment for all projects is CNY 129,301.1 million, with an adjusted total investment of CNY 142,403.87 million, achieving a cumulative investment of CNY 122,945.47 million[95]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[109][110][111]. Environmental and Social Responsibility - The company has invested over 1 billion yuan in poverty alleviation initiatives, establishing four industrial bases in national-level poverty-stricken counties[151]. - The company has implemented a self-monitoring plan for pollutant emissions in accordance with the pollution discharge permit requirements, ensuring timely monitoring and public disclosure[147]. - The company has achieved compliance with various pollutant discharge standards, including wastewater and air emissions[146]. - The company is actively integrating its advantages in traditional Chinese medicine into rural revitalization efforts, contributing to local economic development[151]. Corporate Governance and Compliance - The company has no changes in its board of directors, supervisors, or senior management during the reporting period[130]. - The company has not sold any significant assets or equity during the reporting period[112][115]. - The company did not engage in any significant related party transactions during the reporting period[169]. - The semi-annual financial report was not audited[164]. - There were no significant litigation or arbitration matters during the reporting period[168]. Shareholder Information - The company did not distribute cash dividends or bonus shares for the first half of 2021[131]. - A total of 1,382.50 million restricted stocks were unlocked, with 827.50 million stocks available for trading on June 21, 2021[132]. - The company reported a 43.73% investor participation rate at the 2020 annual general meeting held on May 18, 2021[129].

Financial Performance - The company's revenue for Q1 2021 reached ¥1,638,989,465, representing a 45.56% increase compared to ¥1,125,977,360 in the same period last year[9]. - Net profit attributable to shareholders was ¥193,160,182.56, a 76.68% increase from ¥109,328,729.49 in the previous year[9]. - Basic earnings per share increased by 50.00% to ¥0.06 from ¥0.04 in the previous year[9]. - The company achieved operating revenue of CNY 163,898.95 million, a year-on-year increase of 45.56% driven by increased sales of formula granules and medical devices[22]. - The net profit attributable to shareholders reached CNY 19,316.02 million, reflecting a growth of 76.68% compared to the previous year[28]. - The total operating income for the current period is 97,197,677.62 CNY, an increase from 79,625,295.78 CNY in the previous period, representing a growth of approximately 22.5%[97]. - The net profit for the current period is 190,354,392.50 CNY, compared to 107,171,641.14 CNY in the previous period, reflecting an increase of about 77.5%[92]. - The total profit for the current period is 229,625,920.99 CNY, up from 129,300,782.74 CNY, indicating an increase of around 77.6%[92]. Cash Flow - The net cash flow from operating activities was ¥149,389,822.89, a significant improvement of 956.15% compared to a negative cash flow of ¥17,449,108.42 in the same period last year[9]. - Cash inflow from operating activities totaled CNY 1,780,137,951.91, an increase from CNY 1,178,230,498.53 year-over-year[108]. - Net cash flow from operating activities was CNY 149,389,822.89, recovering from a negative CNY 17,449,108.42 in the previous period[108]. - Cash inflow from investment activities was CNY 437,330,747.77, up from CNY 377,475,031.87 year-over-year[114]. - Net cash flow from investment activities improved to CNY 247,732,490.69, compared to a negative CNY 84,690,151.78 in the previous period[114]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,549,639,671.91, up 3.63% from ¥10,179,628,487.94 at the end of the previous year[9]. - The total liabilities increased to ¥2,962,999,751.73 from ¥2,787,758,169.50, indicating a rise of about 6.2%[77]. - The total assets amounted to ¥10,549,639,671.91, compared to ¥10,179,628,487.94, showing a growth of about 3.6%[77]. - The company's total liabilities and equity as of January 1, 2021, totaled CNY 10,314,662,141.45[119]. - Short-term borrowings decreased by 36.78% to CNY 50,125.22 million, primarily due to reduced repayments of bank loans[22]. Shareholder Information - The net assets attributable to shareholders increased by 2.73% to ¥7,390,822,794.12 from ¥7,194,120,602.32 at the end of the previous year[9]. - The weighted average return on equity was 2.65%, an increase of 1.05% compared to 1.60% in the previous year[9]. - The top shareholder, Chengdu Xingcheng Investment Group Co., Ltd., holds 22.24% of the shares, with a total of 667,997,417 shares[12]. Research and Development - Research and development expenses amounted to CNY 4,108.49 million, up 79.88% year-on-year due to new R&D projects and increased investment[24]. - Research and development expenses increased to 41,084,903.84 CNY from 22,839,875.67 CNY, marking a rise of approximately 79.6%[92]. - The company is committed to addressing industry challenges and enhancing its research and development capabilities to drive innovation in its product lines[34]. Government Subsidies - The company reported a government subsidy of ¥7,212,951.16 during the reporting period[9]. - The company received government subsidies amounting to CNY 622.21 million, a year-on-year increase of 67.33%[24]. Strategic Initiatives - The company plans to enhance its competitive advantage in the traditional Chinese medicine industry through digital transformation initiatives[28]. - The company aims to continue participating in the formulation and application of national standards for formula granules[28]. - The company has established a smart manufacturing project for traditional Chinese medicine granules in Shandong, enhancing its production capacity and supporting the local health industry[29]. - The medical device business has seen significant growth, with a focus on promoting the star product, the fingertip pulse oximeter, and expanding both domestic and international sales channels[30]. - The company is actively participating in the national drug standard formulation process, ensuring compliance with quality control and production standards for traditional Chinese medicine granules[35]. Compliance and Governance - The company has adhered to commitments regarding avoiding competition within the same industry, reducing related party transactions, and maintaining independence during asset restructuring[43]. - The company has maintained compliance with all commitments made during the reporting period, ensuring transparency and accountability[46]. - The company has not reported any overdue commitments that remain unfulfilled during the reporting period[46].